2020
DOI: 10.1016/j.bjid.2020.08.008
|View full text |Cite
|
Sign up to set email alerts
|

Concerns about COVID-19 and arboviral (chikungunya, dengue, zika) concurrent outbreaks

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
16
0
2

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(19 citation statements)
references
References 6 publications
(8 reference statements)
1
16
0
2
Order By: Relevance
“… 9 , 14 A recent study has reported that Brazil has undergone a severe surge of zika, dengue, and chikungunya cases during the ongoing COVID‐19 pandemic. 15 High alerts of arboviral infections create numerous logistic and critical challenges for the already worn‐out healthcare system in Pakistan. A stern, sensible and judicious action plan is required in haste to quell the aggravating dangers of cooccurrence.…”
Section: Tablementioning
confidence: 99%
“… 9 , 14 A recent study has reported that Brazil has undergone a severe surge of zika, dengue, and chikungunya cases during the ongoing COVID‐19 pandemic. 15 High alerts of arboviral infections create numerous logistic and critical challenges for the already worn‐out healthcare system in Pakistan. A stern, sensible and judicious action plan is required in haste to quell the aggravating dangers of cooccurrence.…”
Section: Tablementioning
confidence: 99%
“…To test the current disease state and a possible scenario of overlapped outbreaks, a multiplexed combination of arboviruses and COVID-19 was used. The WHO recommends multiplexing ZIKV, DENV, and CHIKV as an ideal detection method, and this combination was found to allow virus distinction in possible co-circulation situations ( do Rosario and de Siqueira, 2020 ; WHO, 2016 ). Qualitative multiplex immunoassays using a threshold value to define positive or negative results were demonstrated with randomly spiked samples in PBS (i.e., anti-ZIKV NS1, anti-DENV NS1, anti-CHIKV E2, anti-ZIKV/DENV NS1, anti-ZIKV/CHIKV NS1/E2, anti-DENV/CHIKV NS1/E2, anti-ZIKV/DENV/CHIKV NS1/E2, anti-SARS-CoV-2 RBD, and all biomarkers).…”
Section: Resultsmentioning
confidence: 99%
“…En países de bajos y medianos ingresos, donde los arbovirus y otras enfermedades tropicales como el caso de dengue, zika o chikungunya son altamente endémicas, la propagación del SARS-CoV-2 representa un desafío adicional para la salud pública, puesto que estas patologías infecciosas comparten características clínicas, y recientemente, se han descrito reactividad cruzada en pruebas de laboratorio, lo cual, enreda aún más el panorama 31,32 . La posibilidad de tener falsos positivos de dengue en pacientes con infección por SARS-CoV-2 33 , y la posibilidad de falsos positivos para SARS-CoV-2 en pacientes con dengue 34 , podría generar un alto riesgo de diagnósticos erróneos, con consecuencias peligrosas para los pacientes tras abrir la posibilidad de un tratamiento inicial incorrecto o retrazado, lo cual, en casos de pandemia puede ser especialmente preocupante por la necesidad de identificar y aislar de inmediato a pacientes positivos 32,34 .…”
Section: Discussionunclassified